Understood; sales reps for the oral FXa inhibitors will acknowledge the existence of an antidote (assuming it’s approved), but they won’t emphasize this point, IMO. Eliquis and Xarelto are supposed to be inherently safer than warfarin, so having sales reps focus on an antidote might jumble the marketing message. Notably, PFE/BMY and JNJ have clinical-trial collaborations with PTLA for testing Andexanet Alfa, but these collaborations do not extend to commercialization.
In other words, PTLA is probably going to have to promote Andexanet Alfa on its own, rather than counting on Big Pharma to get the job done.
Market Data 
Markets 
AI
